Free Newsletter
Novartis vaccine recalled in U.K.
U.K. authorities have recalled a Novartis meningitis vaccine on fears that 21,000 doses might be contaminated with bacteria. The infant vaccine--sold under the brand name Menjugate--had been ordered by the Department of Health as part of its routine meningitis C vaccination program for all babies. Sixty thousand doses were delivered in January and February, but only 21,000 had been sent out to doctors and clinics.
Regulators said they hadn't received any adverse event reports. The recall is precautionary, they said.
Novartis said it had found traces of Staphylococcus aureus in the solvent in which the vaccine is suspended, during tests on other vials made at the same time as the recalled batches. The company notified U.K. officials Tuesday about the problem and said it wanted to recall those batches.
It's the second vaccine recall in Europe in the last few weeks. Italian authorities pulled doses of Merck's human papillomavirus Gardasil when two girls became ill after receiving shots from the same batch.
- read the story in the Telegraph
- check out the BBC article
Related Articles:
Novartis reports strong meningitis vaccine response
Novartis meningitis vaccine delivers positive data
Novartis pays big for roster of new vaccines
Novartis plots $700M biotech plant
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: